Cybersecurity, What You Don’t Know Can Hurt You!

 

October is Cybersecurity Awareness Month, and in the age of e-commerce, it’s important for businesses to know how to keep their assets protected.  

That’s why host Michelle Dawn Mooney spoke with Richard Negron, Chief Information Officer at Catapult Solutions Group and David Moon, Chief Executive Officer of Arx Nimbus, on all things cybersecurity and how even the things left unknown can be truly harmful.   

“In many cases it’s not that they’re not prepared, it’s that they don’t know the degree of their unpreparedness. And in the cybersecurity profession we are still on a learning curve… we’ve got a long way to go,” Moon said. 

Hackers never sleep. They are constantly looking for ways to get into a system, and to even trick overconfident businesses who assume it wouldn’t happen to them, Negron added.  

One of the greatest amounts of risk exposure seen is with contextual spearfishing where hackers monitor corporate emails and servers.  

“Now through analytics and artificial intelligence, a hacker can be more descriptive when they send phishing emails or texts. They’ll send something familiar to build a level of trust that gets you to respond. Because it only takes one account to be compromised and once a hacker is in, they’ll continue to do reconnaissance until they access the accounts that can do the most damage to a business,” Negron said.  

As threats increase the software and armors to protect businesses also increases that can help in the battle against cybersecurity.  

“One of the things that we do recommend is to go back to the basics, understand where you are today, look, and analyze those vulnerabilities. Then when you [the company] have and address them, focus on the training for both your employees and the end users, so they can understand it is a dual responsibility,” Negron emphasized.  

“We encourage that level of analysis and then there needs to be a discussion internally on how much risk do they need to take on realistically and ask where we need to be on the risk level, how long are we willing to take to get there and what are we willing to spend. Having that understanding helps organizations time and again develop the will to really go after these issues and fund the proper fixes,” Moon concluded.  

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More